Results 81 to 90 of about 39,225 (199)

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer

Advancement of science
Most clinical PARP inhibitors (PARPis) trap PARP1 in a chromatin‐bound state, leading to PARPi‐mediated cytotoxicity. PARPi resistance impedes the treatment of ovarian cancer in clinical practice.
Zhiyan Zhan, Jiarong Zhang, Huisheng Liang, Chong Wang, Li Hong, Wenxue Liu   +5 more
semanticscholar   +1 more source

Basal Activity of a PARP1-NuA4 Complex Varies Dramatically across Cancer Cell Lines

Cell Reports, 2014
Poly(ADP-ribose) polymerases (PARPs) catalyze poly(ADP-ribose) addition onto proteins, an important posttranslational modification involved in transcription, DNA damage repair, and stem cell identity.
Kristin A. Krukenberg, Ruomu Jiang, Judith A. Steen, Timothy J. Mitchison   +3 more
doaj   +1 more source

Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors

bioRxiv
Poly ADP-ribose polymerase 1 (PARP1) is an attractive therapeutic target for cancer treatment. Machine-learning scoring functions constitute a promising approach to discovering novel PARP1 inhibitors.
Klaudia Caba, V. Tran-Nguyen, Taufiq Rahman, Pedro J. Ballester   +3 more
semanticscholar   +1 more source

RET Inhibitor SPP86 Is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Letter]

Drug Design, Development and Therapy
Yingjian Tan, Rui Li Department of Dermatology, Fuzhou First General Hospital, Fuzhou, People’s Republic of ChinaCorrespondence: Rui Li, Email 15773250213@163 ...
Tan Y, Li R
doaj  

PARP1 bound to XRCC2 promotes tumor progression in colorectal cancer

Discover Oncology
Background By complexing poly (ADP-ribose) (PAR) in reaction to broke strand, PAR polymerase1 (PARP1) acts as the key enzyme participated in DNA repair.
Kaiwu Xu, Zhige Yu, Tailiang Lu, Wei Peng, Yongqiang Gong, Chaowu Chen   +5 more
doaj   +1 more source

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Molecular Cancer, 2017
Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-breaks.
Pignochino, Ymera, Capozzi, Federica, D'Ambrosio, Lorenzo, Dell'Aglio, Carmine, Basiricò, Marco, Canta, Marta, Lorenzato, Annalisa, Vignolo Lutati, Francesca, Aliberti, Sandra, Palesandro, Erica, Boccone, Paola, Galizia, Danilo, Miano, Sara, Chiabotto, Giulia, Napione, Lucia, Gammaitoni, Loretta, Sangiolo, Dario, Benassi, Maria Serena, Pasini, Barbara, Chiorino, Giovanna, Aglietta, Massimo, Grignani, Giovanni   +21 more
openaire   +3 more sources

PARP1 inhibits apoptosis of breast cancer cells by regulating RNF144A

Zhongguo aizheng zazhi, 2019
Background and purpose: Breast cancer is the most commonly diagnosed cancer, but its underlying mechanism remains elusive. The previous studies have demonstrated that ring finger protein 144A (RNF144A) regulates the stablity of poly (ADPribose ...
曹金玲, 张方淋, 李大强
doaj  

PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma

International Journal of Cancer
Metastatic melanoma is still a difficult‐to‐treat cancer type owing to its frequent resistance mechanisms to targeted and immunotherapy. Therefore, we aimed to unravel novel therapeutic strategies for melanoma patients.
L. M. Fröhlich, Ana Villar-Miyar, Tamara Heintze, Birgit Sauer, Birgit Schittek   +4 more
semanticscholar   +1 more source

PARP1

Funding Information: This research was funded by the Portuguese National Funding Agency (FCT-MCTES), through Radiation Biology and Biophysics Doctoral Training Programme (RaBBiT, PD/00193/2012), the Applied Molecular Biosciences Unit—UCIBIO (UIDB/04378/2020), the CEFITEC Unit (UIDB/00068/2020), UIDB/04559/2020 (LIBPhys) and UIDP/ 04559/2020 (LIBPhys ...
Conceição, Carlota J.F., Moe, Elin, Ribeiro, Paulo A., Raposo, Maria   +3 more
openaire   +1 more source

Update on PARP1 inhibitors in ovarian cancer

Annals of Oncology, 2011
The clinical development of PARP inhibitors for the treatment of tumors deficient in BRCA1 or BRCA2 is based on the concept of synthetic lethality. From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population ...
openaire   +3 more sources